Dataciencia

Colección SciELO Chile

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Indexado

WoS	WOS:000311303700014
Scopus	SCOPUS_ID:84869100588

DOI

10.1093/EURHEARTJ/EHS274

Año

2012

Tipo

artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras

Abstract

In patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban.

Revista

Revista	ISSN
European Heart Journal	0195-668X

Métricas Externas

PlumX	Altmetric	Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Plumx: https://plumanalytics.com/learn/about-metrics/
Altmetric: https://www.altmetric.com/about-altmetrics/what-are-altmetrics/
Dimensions: https://www.dimensions.ai/why-dimensions/

Disciplinas de Investigación

WOS
Cardiac & Cardiovascular Systems

Scopus
Sin Disciplinas

SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional

Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.

Autores - Afiliación

Ord.	Autor	Género	Institución - País
1	Hohnloser, Stefan	Hombre	Goethe Univ Frankfurt - Alemania Goethe-Universität Frankfurt am Main - Alemania
2	Hijazi, Ziad	Hombre	UPPSALA UNIV - Suecia Akademiska Sjukhuset - Suecia Uppsala Universitet - Suecia
3	Thomas, Laine	Mujer	Duke Univ - Estados Unidos Duke University Medical Center - Estados Unidos Duke Clinical Research Institute - Estados Unidos
4	Alexander, John H.	Hombre	Duke Univ - Estados Unidos Duke University Medical Center - Estados Unidos Duke Clinical Research Institute - Estados Unidos
5	Amerena, John	Hombre	Deakin Univ - Australia Deakin University - Australia
6	Hanna, Michael	Hombre	Bristol Myers Squibb Co - Estados Unidos Bristol-Myers Squibb - Estados Unidos
7	Keltai, Matyas	-	Semmelweis Univ - Hungría Semmelweis Egyetem - Hungría
8	LANAS, F	Hombre	Universidad de La Frontera - Chile
9	Lopes, Renato D.	Hombre	Duke Univ - Estados Unidos Duke University Medical Center - Estados Unidos Duke Clinical Research Institute - Estados Unidos
10	Lopez-Sendon, Jose	Hombre	Hosp Univ La Paz - España Hospital Universitario La Paz - España
11	Granger, Christopher B.	Hombre	Duke Univ - Estados Unidos Duke University Medical Center - Estados Unidos Duke Clinical Research Institute - Estados Unidos
12	Wallentin, Lars	Hombre	UPPSALA UNIV - Suecia Akademiska Sjukhuset - Suecia Uppsala Universitet - Suecia

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Origen de Citas Identificadas

Muestra la distribución de países cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 0.49 %
Citas No-identificadas: 99.51 %

Muestra la distribución de instituciones nacionales o extranjeras cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 0.49 %
Citas No-identificadas: 99.51 %

Financiamiento

Fuente
Novartis
GlaxoSmithKline
Bristol-Myers Squibb
Medtronic
Sanofi-Aventis
Sanofi
Bayer
Pfizer
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Novartis Pharma
Merck
F. Hoffmann-La Roche
Medtronic foundation
Merck KGaA
Johnson Johnson
BMS
Lilly
Astellas Pharma
Astellas
Bristol-Myers Squibb/Pfizer
St Jude Medical
Otsuka
Schering-Plough
Regado Biosciences
Berlin Mathematical School
British Microcirculation Society
Otsuka Pharmaceutical
Ortho-McNeil-Janssen Pharmaceuticals
Merck/Schering-Plough
Medicine's Company
Hoffman-La Roche
Cardiome
PolyMedix
BI
DaiichiSankyo
Regado Biosciences, Evolva, Portola
Schering-Plough/Merck
Medicine’s Company

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos

Agradecimiento
Conflict of interest: S. H. H. reports receiving consulting fees from Sanofi-aventis, Cardiome, BMS, BI, Johnson & Johnson, and Pfizer, research grants from Sanofi-aventis and St Jude Medical; and lecture fees from Sanofi-aventis, St Jude Medical, Pfizer, BMS, Medtronic, and BI. Z.H. reports receiving lecture fees and an institutional research grant from Boehringer Ingelheim. J.A. reports receiving lecture and consulting fees from Bristol-Myers Squibb and Pfizer. J.H.A. reports receiving grants from Bristol-Myers Squibb, Merck/Schering-Plough, and Regado Biosciences; travel support from Bristol-Myers Squibb; and consulting fees from Bristol-Myers Squibb, Pfizer, Merck/Schering-Plough, AstraZeneca, Boehringer Ingelheim, Ortho-McNeil-Janssen Pharmaceuticals, PolyMedix, Regado Biosciences, Bayer, and DaiichiSankyo. M. H. is an employee of Bristol-Myers Squibb and receiving stock as a part of his compensation. M. K. reports receiving travel support from Bristol-Myers Squibb. F. L. reports receiving grant and travel support from Bristol-Myers Squibb/Pfizer. R. D. L. reports receiving grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and DaiichiSankyo and consulting fees from Bristol-Myers Squibb. J.L.-S. reports receiving grants from Bristol-Myers Squibb, Boehringer Ingelheim, and Bayer and consulting fees from Boehringer Ingelheim. C. B. G. reports receiving grants from Bristol-Myers Squibb, Boehringer Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic foundation, Merck, Sanofi-aventis, and the Medicine's Company; consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, AstraZeneca, Lilly, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-aventis, and the Medicine's Company; and travel support from Pfizer, Novartis, Otsuka, and Hoffmann-La Roche. L. W. reports receiving research grants from AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline; being a consultant for Merck/Schering-Plough, Regado Biosciences, Evolva, Portola, C.S.L. Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough; and honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck.
The ARISTOTLE trial was funded by Bristol-Myers Squibb and Pfizer. Duke Clinical Research Institute received funding from BMS for the analysis and manuscript preparation performed by L.T.

Agradecimiento

Conflict of interest: S. H. H. reports receiving consulting fees from Sanofi-aventis, Cardiome, BMS, BI, Johnson & Johnson, and Pfizer, research grants from Sanofi-aventis and St Jude Medical; and lecture fees from Sanofi-aventis, St Jude Medical, Pfizer, BMS, Medtronic, and BI. Z.H. reports receiving lecture fees and an institutional research grant from Boehringer Ingelheim. J.A. reports receiving lecture and consulting fees from Bristol-Myers Squibb and Pfizer. J.H.A. reports receiving grants from Bristol-Myers Squibb, Merck/Schering-Plough, and Regado Biosciences; travel support from Bristol-Myers Squibb; and consulting fees from Bristol-Myers Squibb, Pfizer, Merck/Schering-Plough, AstraZeneca, Boehringer Ingelheim, Ortho-McNeil-Janssen Pharmaceuticals, PolyMedix, Regado Biosciences, Bayer, and DaiichiSankyo. M. H. is an employee of Bristol-Myers Squibb and receiving stock as a part of his compensation. M. K. reports receiving travel support from Bristol-Myers Squibb. F. L. reports receiving grant and travel support from Bristol-Myers Squibb/Pfizer. R. D. L. reports receiving grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and DaiichiSankyo and consulting fees from Bristol-Myers Squibb. J.L.-S. reports receiving grants from Bristol-Myers Squibb, Boehringer Ingelheim, and Bayer and consulting fees from Boehringer Ingelheim. C. B. G. reports receiving grants from Bristol-Myers Squibb, Boehringer Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic foundation, Merck, Sanofi-aventis, and the Medicine's Company; consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, AstraZeneca, Lilly, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-aventis, and the Medicine's Company; and travel support from Pfizer, Novartis, Otsuka, and Hoffmann-La Roche. L. W. reports receiving research grants from AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline; being a consultant for Merck/Schering-Plough, Regado Biosciences, Evolva, Portola, C.S.L. Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough; and honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck.

The ARISTOTLE trial was funded by Bristol-Myers Squibb and Pfizer. Duke Clinical Research Institute received funding from BMS for the analysis and manuscript preparation performed by L.T.